Immune checkpoint inhibitors (ICIs), including PD-1, PD-L1, and CTLA-4 inhibitors, can reactivate the anti-tumor response of the innate immune system by blocking the inhibitory immune checkpoint receptors present in TME or on tumor cells55,56. This evidence concerns the gene CTLA4 and neoplasm.